Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, ...

Centrally acting agents like phentermine/topiramate and naltrexone/bupropion aid weight reduction but lack MASLD-specific data and carry potential risks such as hepatotoxicity, teratogenicity, or ...

Ascletis Pharma reveals ASC47, a promising weight loss drug, shows over 56% greater body weight reduction when combined with ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...

While only two therapies have so far gained approval, the broader pipeline paints a picture of strong research and ...

Metabolic-associated steatohepatitis (MASH) can cause liver damage, which can be stopped or reversed if it’s caught early. Learn more about the treatments that may help.

The European Association for the Study of Obesity (EASO) has called for GLP-1 agonists from Novo Nordisk and Eli Lilly to be ...

The reason Viking Therapeutics looks attractive at current levels is that, while it still has a highly attractive mid-stage ...